Thus, the AKT/c-Met mouse hepatocarcinogenesis model might represent a valid preclinical tool to investigate the therapeutic potential of targeted therapies against HCC subsets characterized by elevated levels of AKT and c-Met [115]. This evidence concerns the gene AKT1 and hepatocellular carcinoma.